{"filing":{"accession_number":"0001193125-26-353308","cik":"0001314102","ticker":"EYPT","company_name":"EyePoint, Inc.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"eypt-20260817.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-20260817.htm"},"events":[{"id":28148,"run_id":25731,"accession_number":"0001193125-26-353308","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"EyePoint announced topline data from LUGANO, a pivotal Phase 3 clinical trial for DURAVYU in wet AMD. While the primary endpoint was not achieved in the full dataset, the company disclosed clinically meaningful secondary endpoint results (42% reduction in treatment burden, 76% supplement-free rates, favorable safety profile) and signaled plans for an NDA filing in 1H 2027 pending results from the second trial (LUCIA) expected in Q4 2026. This is a material clinical milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the product's regulatory and commercial prospects, but does not fit the earnings_release category (no financial results) or other specific event types.","company_name":"EyePoint, Inc.","ticker":"EYPT","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":29973,"accession_number":"0001193125-26-353308","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"EyePoint announced topline data from LUGANO, a pivotal Phase 3 clinical trial for DURAVYU in wet AMD. While the primary endpoint was not achieved in the full dataset, the company disclosed clinically meaningful secondary endpoint results (42% reduction in treatment burden, 76% supplement-free rates, favorable safety profile) and signaled plans for an NDA filing in 1H 2027 pending results from the second trial (LUCIA) expected in Q4 2026. This is a material clinical milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the product's regulatory and commercial prospects, but does not fit the earnings_release category (no financial results) or other specific event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:51:40.154637+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29973,"accession_number":"0001193125-26-353308","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"EyePoint announced topline data from LUGANO, a pivotal Phase 3 clinical trial for DURAVYU in wet AMD. While the primary endpoint was not achieved in the full dataset, the company disclosed clinically meaningful secondary endpoint results (42% reduction in treatment burden, 76% supplement-free rates, favorable safety profile) and signaled plans for an NDA filing in 1H 2027 pending results from the second trial (LUCIA) expected in Q4 2026. This is a material clinical milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the product's regulatory and commercial prospects, but does not fit the earnings_release category (no financial results) or other specific event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:51:40.154637+00:00","company_name":"EyePoint, Inc.","ticker":"EYPT","filing_date":"2026-08-17"}]}